CMA
SUPN icon

Cedar Mountain Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Cedar Mountain Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.51K Hold
183
– – ﹤0.01% 537
2026
Q1 		$9.46K Buy
+183
New +$9.32K ﹤0.01% 473

Other funds holding SUPN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

Cedar Mountain Advisors's SUPN Position: Q2 2026 in Review

Cedar Mountain Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 183 shares worth $8.51K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Cedar Mountain Advisors first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.46K in Q1 2026. 27 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Cedar Mountain Advisors held 183 shares of Supernus Pharmaceuticals worth $8.51K as of Q2 2026.
  • Cedar Mountain Advisors left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #537 holding.
  • Cedar Mountain Advisors first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Cedar Mountain Advisors's Supernus Pharmaceuticals position peaked at $9.46K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.